Test of Time Points to Durability of Efalizumab Efficacy and Safety

Chicago - The Biologics License Application for efalizumab (Raptiva) for the treatment of moderate-to-severe plaque psoriasis is set to undergo review by the FDA Dermatologic and Ophthalmic Drugs Advisory Committee this month.

Related Videos
Related Content

Breast Care for Pregnant and Lactating Patients

March 28th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Improve Patient Outcomes With Better Language Access

March 28th 2023

The Cutaneous Connection- Episode 35: QRPs and the Dermatology Practice

December 2nd 2021

Recent Povorcitinib 2b Study Shows Improved Repigmentation

March 27th 2023

Self-Esteem in Males with Alopecia Improved by Hair Transplantation

March 27th 2023

Breast Care for Pregnant and Lactating Patients

March 28th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Improve Patient Outcomes With Better Language Access

March 28th 2023

The Cutaneous Connection- Episode 35: QRPs and the Dermatology Practice

December 2nd 2021

Recent Povorcitinib 2b Study Shows Improved Repigmentation

March 27th 2023

Self-Esteem in Males with Alopecia Improved by Hair Transplantation

March 27th 2023

Breast Care for Pregnant and Lactating Patients

March 28th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Improve Patient Outcomes With Better Language Access

March 28th 2023

The Cutaneous Connection- Episode 35: QRPs and the Dermatology Practice

December 2nd 2021

Recent Povorcitinib 2b Study Shows Improved Repigmentation

March 27th 2023

Self-Esteem in Males with Alopecia Improved by Hair Transplantation

March 27th 2023
© 2023 MJH Life Sciences

All rights reserved.